Information  X 
Enter a valid email address

MGC Pharmctls Ltd OrdNpv (MXC)

Date Time Source Announcement
22 Sep 2021 8:36 am
RNS
Notification of ASX Market Announcements
20 Sep 2021 11:03 am
RNS
Director/PDMR Shareholding
  10:57 am
RNS
Notification of ASX Market Announcements
15 Sep 2021 7:04 am
RNS
ArtemiC Update - Approval for sale in EU & Results
13 Sep 2021 3:43 pm
RNS
Director/PDMR Shareholding
  7:00 am
RNS
Landmark UK Import Permit granted for CannEpil+
09 Sep 2021 11:45 am
RNS
Notification of ASX Market Announcements
  11:35 am
RNS
Notification of ASX Market Announcements
08 Sep 2021 9:05 am
RNS
Second Price Monitoring Extn
  9:00 am
RNS
Price Monitoring Extension
02 Sep 2021 9:05 am
RNS
Second Price Monitoring Extn
  9:00 am
RNS
Price Monitoring Extension
  7:00 am
RNS
CimetrA import approval granted in India
01 Sep 2021 7:00 am
RNS
Preliminary Financial Report for 30 June 2021
31 Aug 2021 7:00 am
RNS
Proposed Issue of Securities and Appendix 3B
27 Aug 2021 9:00 am
RNS
Holder Update - MXCOE Listed Options
26 Aug 2021 9:05 am
RNS
Second Price Monitoring Extn
  9:00 am
RNS
Price Monitoring Extension
  7:10 am
RNS
MGC Pharma executes US$24m agreement with US firm
12 Aug 2021 1:21 pm
RNS
Results of General Meeting
06 Aug 2021 8:47 am
RNS
General Meeting Information and Webinar
03 Aug 2021 7:00 am
RNS
Expiry of Share Options
26 Jul 2021 7:00 am
RNS
Quarterly Results
16 Jul 2021 7:56 am
RNS
Amendment to Expiry of Share Options
15 Jul 2021 7:17 am
RNS
Cannabinoid Patent Application Submitted
13 Jul 2021 10:52 am
RNS
Expiry of Share Options
  9:38 am
RNS
Issue of Shares and Cleansing Statement
12 Jul 2021 7:00 am
RNS
Phase III CimetrAT Clinical Trial Commences
09 Jul 2021 9:16 am
RNS
Cleansing Notice and Appendix 2A
  7:00 am
RNS
Notice of GM
15 Jun 2021 7:00 am
RNS
CannEpil - Primary Care Reimbursement in Ireland
09 Jun 2021 7:24 am
RNS
Appointment of Company Secretary
25 May 2021 7:00 am
RNS
2021 Clinical Trials Program Update
17 May 2021 7:58 am
RNS
CimetrA Patent Submitted to European IP Office
14 May 2021 7:59 am
RNS
Appendix 3G
  7:50 am
RNS
Appendix 2A - Issue of Shares
07 May 2021 7:27 am
RNS
Research Update - ArtemiC
06 May 2021 2:00 pm
RNS
Price Monitoring Extension
  7:31 am
RNS
ASX Trading Halt
04 May 2021 7:00 am
RNS
New ArtemiC Order Received From Swiss PharmaCan AG
28 Apr 2021 7:00 am
RNS
Application to Health Canada for ArtemiC Approval
27 Apr 2021 7:00 am
RNS
Quarterly Results
22 Apr 2021 7:00 am
RNS
Acquisition of MediCaNL
21 Apr 2021 12:36 pm
RNS
Issue of Equity
09 Apr 2021 7:00 am
RNS
Investor Presentation
08 Apr 2021 11:00 am
RNS
Corporate Update
07 Apr 2021 7:08 am
RNS
ArtemiC Rescue First Delivery and March Revenue
31 Mar 2021 12:54 pm
RNS
GM Statement
24 Mar 2021 9:03 am
RNS
Appendix 2A - Issue of Shares
22 Mar 2021 7:30 am
RNS
Phase III Clinical Trial of CimetrA Approved
19 Mar 2021 7:00 am
RNS
Notice of GM
09 Mar 2021 8:19 am
RNS
Appendix 2A - Issue of Shares
  7:00 am
RNS
Director/PDMR Shareholding
02 Mar 2021 7:00 am
RNS
Increased initial supply agreement for ArtemiC
26 Feb 2021 7:17 am
RNS
Notice of GM
  7:00 am
RNS
Half-year Report
25 Feb 2021 9:05 am
RNS
Second Price Monitoring Extn
  9:00 am
RNS
Price Monitoring Extension
19 Feb 2021 4:41 pm
RNS
Second Price Monitoring Extn
  4:36 pm
RNS
Price Monitoring Extension

a d v e r t i s e m e n t